Therapy Directory

Abemaciclib clinical trials

Directory of U.S. ClinicalTrials.gov public records that list Abemaciclib as a study intervention. Browse Abemaciclib recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 7:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

188

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Breast Cancer
Interventions: Not listed
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Breast Cancer, Metastasis
Interventions: Abemaciclib, Bicalutamide; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years to 90 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2028
U.S. locations: 3
States / cities: New York, New York

Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Negative Breast Carcinoma, Metastatic Hormone Receptor-Positive Breast Carcinoma
Interventions: CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine, Capecitabine, Computed Tomography, Cyclin-Dependent Kinase 4 Inhibitor, Cyclin-Dependent Kinase 6 Inhibitor, F-18 16 Alpha-Fluoroestradiol, Hormone Therapy, Positron Emission Tomography, Biopsy Procedure, Biospecimen Collection, Abemaciclib; Biological · Drug · Procedure
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Breast Cancer, Breast Cancer Metastatic, Hormone Receptor Positive Tumor, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Ovarian Cancer, CCNE1 Amplification, Solid Tumor, Advanced Cancer, Metastatic Cancer
Interventions: INX-315, Fulvestrant, Abemaciclib; Drug
Lead sponsor: Incyclix Bio; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 15
States / cities: Orlando, Florida • Atlanta, Georgia • Augusta, Georgia + 10 more

Conditions: Endometrial Cancer
Interventions: Atezolizumab - 28 Day Cycle, Bevacizumab, Ipatasertib, Talazoparib, Trastuzumab emtansine, Tiragolumab, Atezolizumab - 21 Day Cycle, Inavolisib, Letrozole, Giredestrant, Abemaciclib; Drug
Lead sponsor: Alliance Foundation Trials, LLC.; Other
Eligibility: 18 Years and older · Female only
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 21
States / cities: Duarte, California • San Francisco, California • Washington D.C., District of Columbia + 18 more

Conditions: Breast Cancer
Interventions: Abemaciclib, Elacestrant; Drug
Lead sponsor: Criterium, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 4
States / cities: Aurora, Colorado • Miami Beach, Florida • Durham, North Carolina + 1 more

Conditions: Meningioma
Interventions: Abemaciclib, Placebo; Drug
Lead sponsor: Nader Sanai; Other
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Endometrial Cancer
Interventions: Abemaciclib, Letrozole; Drug
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: 18 Years and older · Female only
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 29
States / cities: Mobile, Alabama • Anchorage, Alaska • Greenwich, Connecticut + 24 more

Conditions: Glioblastoma, GBM, Glioma
Interventions: Abemaciclib, LY3214996; Drug
Lead sponsor: Nader Sanai; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 3
States / cities: Chandler, Arizona • Phoenix, Arizona • Scottsdale, Arizona

Conditions: Relapsed Solid Tumor, Refractory Solid Tumor
Interventions: Abemaciclib, Irinotecan, Temozolomide, Dinutuximab, GM-CSF; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: Up to 21 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 12
States / cities: Phoenix, Arizona • Los Angeles, California • Oakland, California + 9 more

Conditions: Breast Cancer
Interventions: Abemaciclib; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Breast Cancer, HER-2 Positive Breast Cancer
Interventions: Resistant Potato Starch, Placebo control; Dietary Supplement
Lead sponsor: University of Vermont Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2031
U.S. locations: 1
States / cities: Burlington, Vermont

About this Abemaciclib clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Abemaciclib as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
How to narrow results: Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Abemaciclib.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Abemaciclib clinical trials

Filter and sort this therapy

Live official records

A Study of Real-World Treatment Patterns and Outcomes Among HR+/HER2- Metastatic Breast Cancer Patients Treated With First-Line CDK4/6 Inhibitors

Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer

A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer

Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer

A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer

Phase Ib/II Trial of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/Her2- Breast Cancer

Abemaciclib in Newly Diagnosed Meningioma Patients

Abemaciclib and Letrozole to Treat Endometrial Cancer

LY3214996 Plus Abemaciclib in Recurrent Glioblastoma Patients

A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma

Abemaciclib for Patients With Retinoblastoma-Positive, Triple Negative Metastatic Breast Cancer

Gut Microbiome Changes During Abemaciclib Therapy in Breast Cancer

About this Abemaciclib clinical trials directory page